Continuous versus intermittent infusion of human antithrombin III concentrate in the immediate postoperative period after liver transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Bo Rim | - |
dc.contributor.author | Lim, Leerang | - |
dc.contributor.author | Choi, YoungRok | - |
dc.contributor.author | Yi, Nam-Joon | - |
dc.contributor.author | Lee, Kwang-Woong | - |
dc.contributor.author | Suh, Kyung-Suk | - |
dc.contributor.author | Yu, Kyung-Sang | - |
dc.contributor.author | Sohn, Jin Young | - |
dc.contributor.author | Jeong, Raewon | - |
dc.contributor.author | Oh, Jaeseong | - |
dc.contributor.author | Ryu, Ho Geol | - |
dc.date.accessioned | 2023-06-09T03:40:04Z | - |
dc.date.available | 2023-06-09T03:40:04Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 1752-8054 | - |
dc.identifier.issn | 1752-8062 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/63223 | - |
dc.description.abstract | Antithrombin-III (AT-III) concentrates have been used in the immediate postoperative period after liver transplantation to prevent critical thrombosis. We aimed to investigate a more appropriate method for AT-III concentrate administration to maintain plasma AT-III activity level within the target range. In this randomized controlled trial, 130 adult patients undergoing living-donor liver transplantation were randomized to either the intermittent group or continuous group. In the intermittent group, 500 international units (IU) of AT-III concentrate were administered after liver transplantation and repeated every 6 h for 72 h. In the continuous group, 3000 IU of AT-III were continuously infused for 71 h after a loading dose of 2000 IU over 1 h. Plasma AT-III activity level was measured at 12, 24, 48, 72, and 84 h from the first AT-III administration. The primary outcome was the target (80%–120%) attainment rate at 72 h. Target attainment rates at other timepoints and associated complications were collected as secondary outcomes. A total of 107 patients were included in the analysis. The target attainment rates at 72 h post-dose were 30% and 62% in the intermittent group and continuous group, respectively (p = 0.003). Compared to the intermittent group, patients in the continuous group reached the target level more rapidly (12 vs. 24 h, median time, p < 0.001) and were more likely to remain in the target range until 84 h. For maintaining the target plasma AT-III activity level after living-donor liver transplantation, continuous infusion of AT-III seemed to be more appropriate compared to the conventional intermittent infusion regimen. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Wiley-Blackwell | - |
dc.title | Continuous versus intermittent infusion of human antithrombin III concentrate in the immediate postoperative period after liver transplantation | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/cts.13521 | - |
dc.identifier.scopusid | 2-s2.0-85153528452 | - |
dc.identifier.wosid | 000976805700001 | - |
dc.identifier.bibliographicCitation | Clinical and Translational Science, v.16, no.7, pp 1177 - 1185 | - |
dc.citation.title | Clinical and Translational Science | - |
dc.citation.volume | 16 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1177 | - |
dc.citation.endPage | 1185 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordPlus | COAGULATION | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | DISEASE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.